Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220706 | 0.91 | RAB9A (0.38) | CYP2C19LMNARAB9ADPP4KDM4E | |
| SCHEMBL3692484 | 0.78 | EPHX2 (0.33) | LMNARIPK1 | |
| SCHEMBL29107947 | 0.76 | HCRTR2 (0.36) | RIPK1 | |
| SCHEMBL6615474 | 0.75 | EPHX2 (0.31) | LMNA | |
| SCHEMBL4916237 | 0.75 | LMNA (0.34) | CYP2C19LMNARAB9A | |
| SCHEMBL2165891 | 0.75 | HCRTR2 (0.36) | DPP4 | |
| SCHEMBL4916247 | 0.75 | LMNA (0.34) | CYP2C19LMNARAB9A | |
| SCHEMBL2247974 | 0.75 | HSD17B10 (0.35) | CYP2C19LMNARAB9ARIPK1DPP4 | |
| SCHEMBL5430851 | 0.75 | SMYD3 (0.37) | CYP2C19CYP2D6OPRK1NPY2REPHX1 | |
| SCHEMBL28673235 | 0.75 | KMT2A (0.38) | CYP2C19CYP2D6EPHX1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | AOC3, AOC2, TPH2 | CYP2C19 777/4885CYP2D6 175/4885OPRK1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.